Clinical Trials News

SOLON, Ohio--(BUSINESS WIRE)--Multi Radiance Medical (MRM), a global leader in Super Pulsed Laser therapy technology and photobiomodulation research, announces that the U.S. Food and Drug Administration (FDA) has granted NHN 510(k) clearance for the adjunctive use of the MR5 ACTIV PRO Super Pulsed Laser for the temporary relief of pain associated with lateral epicondylitis. Lateral epicondylitis (LE) is one of the most common causes of elbow pain, affecting an estimated 10.5 million adults annu...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that the Company’s clinical program for fasedienol nasal spray for the acute treatment of social anxiety disorder has achieved the minimum patient exposures as recommended under ICH E1, the international regulatory...

MINNEAPOLIS--(BUSINESS WIRE)--Vergent Bioscience, a clinical-stage biotechnology company advancing molecularly targeted intraoperative imaging, today announced the appointment of Adam Gridley as President and Chief Executive Officer. Mr. Gridley succeeds John Santini, Ph.D., who will transition to the role of Chief Technology Officer, continuing to lead the company’s scientific innovation and long-term technology strategy. Mr. Gridley brings more than 30 years of commercial and late-stage clini...

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, developer of the leading AI model for tumor and immune biology, today announced it has been named a Diamond winner in the 2026 Pinnacle Awards for Healthcare. Recognized in the Innovator in Biotech Solutions category, BostonGene was honored for its work in enabling better decision-making across drug development. The Pinnacle Awards celebrate global excellence and innovation, highlighting organizations that are advancing medical technology and redefin...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that the company is participating in the UBS 3rd Virtual CNS Day being held on June 15, 2026. During the virtual event, members of Enveric’s management team will conduct one-on-one meetings with registered investors to discuss the company’s busine...

AUSTIN, Texas--(BUSINESS WIRE)--Zetagen Therapeutics, a clinical‑stage biopharmaceutical company developing novel therapies for primary and metastatic breast cancer, today announced preliminary topline results from its Phase 2a clinical study evaluating ZetaMet™ (Zeta BC 003) in subjects with metastatic breast cancer (MBC) with lytic bone lesions. In this open‑label study, no skeletal‑related events (SREs) or fractures were observed, no treatment‑emergent adverse events (AEs) or serious adverse...

SAN MATEO, Calif. & DALLAS--(BUSINESS WIRE)--Curve Biosciences Unveils Scientific Advisory Board Guiding the Advancement of Whole-Body Intelligence for Chronic Disease...

BOSTON--(BUSINESS WIRE)--Syntis Bio, Inc. a clinical-stage biopharmaceutical company advancing novel oral therapeutics that uniquely leverage the small intestine, today announced the appointment of Matthew Dallas as Chief Financial Officer, who brings more than 25 years of financial expertise and management experience in the life sciences industry. “With Matt’s appointment, we continue to assemble a leadership team with the expertise and experience needed to scale Syntis Bio’s financial and bus...

VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced the top-line results from its BEACON real-world study evaluating provider-reported cognitive, behavioral, functional, and tolerability outcomes among long-term care residents with mild to moderate Alzheimer’s disease who were receiv...

MILAN & SAN MATEO, Calif.--(BUSINESS WIRE)--Dompé advances Phase 3 study of Cenegermin-bkbj (a rhNGF) for PCED, a rare condition with high unmet clinical need....